Can Treating Persistent Inflammation Limit Protein Energy Wasting?

Seminars in Dialysis

Volumn 26, Issue 1, 2013, Pages 16-19

  Stenvinkel, Peter ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT;

CHRONIC KIDNEY FAILURE; EDITORIAL; HUMAN; INFLAMMATION; METABOLISM; METHODOLOGY; NUTRITIONAL SUPPORT; PROTEIN DEFICIENCY;

ANTI-INFLAMMATORY AGENTS; HUMANS; INFLAMMATION; NUTRITIONAL SUPPORT; PROTEIN DEFICIENCY; RENAL INSUFFICIENCY, CHRONIC;

EID: 84872975177     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/sdi.12020     Document Type: Editorial

References (34)

1. Delano MJ, Moldawer LL: The origins of cachexia in acute and chronic inflammatory diseases. Nutr Clin Pract 21:68-81, 2006
2. Stenvinkel P, Ketteler M, Johnson RJ, Lindholm B, Pecoits-Filho R, Riella M, et al.: Interleukin-10, IL-6 and TNF-a: central factors in the altered cytokine network of end-stage renal disease - the good, the bad and the ugly. Kidney Int 67:1216-1233, 2005
3. Miyamoto T, Carrero JJ, Stenvinkel P: Inflammation as a risk factor and target for therapy in chronic kidney disease. Curr Opin Nephrol Hypertens 20:662-668, 2011
4. Ashby DR, Ford HE, Wynne KJ, Wren AM, Murphy KG, Busbrige M, Brown EA, Taube DH, Ghatei MA, Tam FW, Bloom SR, Choi P: Sustained appetite improvement in malnourished dialysis patients by daily ghrelin treatment. Kidney Int 76:199-206, 2009
5. Deboer MD, Zhu X, Levasseur PR, Inui A, Hu Z, Han G, Mitch WE, Taylor JE, Halem HA, Dong JZ, Datta R, Culler MD, Marks DL: Ghrelin treatment of chronic kidney disease: improvements in lean body mass and cytokine profile. Endocrinology 149:827-835, 2008
6. Carrero JJ, Nakashima A, Qureshi AR, Lindholm B, Heimbürger O, Bárány P, Stenvinkel P: Protein-energy wasting modifies the association of ghrelin with inflammation, leptin, and mortality in hemodialysis patients. Kidney Int 79:749-756, 2011
7. Miyamoto T, Carrero JJ, Qureshi AR, Anderstam B, Heimburger O, Barany P, Lindholm B, Stenvinkel P: Circulating follistatin in patients with chronic kidney disease: implications for muscle strength, bone mineral density, inflammation, and survival. Clin J Am Soc Nephrol 24:1001-1008, 2011
8. Zhang L, Rajan V, Lin E, Hu Z, Han HQ, Zhou X, Song Y, Min H, Wang X, Du J, Mitch WE: Pharmacological inhibition of myostatin suppresses systemic inflammation and muscle atrophy in mice with chronic kidney disease. FASEB J 25:1653-1663, 2011
9. Friedman AN, Moe SM, Perkins SM, Li Y, Watkins BA: Fish consumption and omega-3 fatty acid status and determinants in long-term hemodialysis. Am J Kidney Dis 47:1064-1071, 2006
10. Saifullah A, Watkins BA, Saha C, Li Y, Moe SM, Friedman AN: Oral fish oil supplementation raises blood omega-3 levels and lowers C-reactive protein in haemodialysis patients--a pilot study. Nephrol Dial Transpl 22:3561-3567, 2007
11. Himmelfarb J, Phinney S, Ikizler TA, Kane J, McMonagle E, Miller G: Gamma-tocopherol and docosahexaenoic acid decrease inflammation in dialysis patients. J Renal Nutr 17:296-304, 2007
12. Hsu SP, Wu MS, Yang CC, Huang KC, Liou SY, Hsu SM, Chien CT: Chronic green tea extract supplementation reduces hemodialysis-enhanced production of hydrogen peroxide and hypochlorous acid, atherosclerotic factors, and proinflammatory cytokines. Am J Clin Nutr 86:1539-1547, 2007
13. Shema-Didi L, Sela S, Ore L, Shapiro G, Geron R, Moshe G, Kristal B: One year of pomegranate juice intake decreases oxidative stress, inflammation and incidence of infections in hemodialysis patients: a randomized placebo-controlled trial. Free Radic Biol Med 53:297-304, 2012
14. Fanti P, Asmis R, Stephenson TJ, Sawaya BP, Franke AA: Positive effect of dietary soy in ESRD patients with systemic inflammation-correlation between blood levels of the soy isoflavones and the acute-phase reactants. Nephrol Dial Transpl 21:2239-2246, 2006
15. Krishnamurthy VM, Wei G, Baird BC, Murtaugh M, Chonchol MB, Raphael KL, Greene T, Beddhu S: High dietary fiber intake is associated with decreased inflammation and all-cause mortality in patients with chronic kidney disease. Kidney Int 81:300-306, 2012
16. Brymora A, Flisiński M, Johnson RJ, Goszka G, Stefańska A, Manitius J: Low-fructose diet lowers blood pressure and inflammation in patients with chronic kidney disease. Nephrol Dial Transpl 27:608-612, 2012
17. Goicoechea M, de Vinuesa SG, Verdalles U, Ruiz-Caro C, Ampuero J, Rincón A, Arroyo D, Luño J: Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 5:1388-1393, 2010
18. Carrero JJ, Stenvinkel P: Inflammation in end-stage renal disease - what have we learned in 10years? Semin Dial 23:498-509, 2010
19. Ridker PM, MacFadyen J, Cressman M, Glynn RJ: Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial. J Am Coll Cardiol 55:1266-1273, 2010
20. Krane V, Winkler K, Drechsler C, Lilienthal J, März W, Wanner C: Effect of atorvastatin on inflammation and outcome in patients with type 2 diabetes mellitus on hemodialysis. Kidney Int 74:1461-1467, 2008
21. Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Grönhagen-Riska C, De Lima JJ, Lins R, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Sci D, Süleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wüthrich RP, Gottlow M, Johnsson E, Zannad F; AURORA Study Group: Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 360:1395-1407, 2009
22. Stenvinkel P, Andersson A, Wang T, Lindholm B, Bergström J, Palmblad J, Heimbürger O, Cederholm T: Do ACE-inhibitors suppress tumor necrosis factor-a production in advanced chronic renal failure? J Int Med 246:503-507, 1999
23. Yilmaz M, Sonmez A, Carrero JJ, Saglam M, Eyileten T, Caglar K, Kirkpantur A, Celik T, Oguz Y, Vural A, Yenicesu M, Lindholm B, Stenvinkel P: Effect of renin angiotensin system blockade on pentraxin 3 levels in diabetic patients with proteinuria. Clin J Am Soc Nephrol 4:535-541, 2009
24. Yilmaz MI, Carrero JJ, Martín-Ventura JL, Sonmez A, Saglam M, Celik T, Yaman H, Yenicesu M, Eyileten T, Moreno JA, Egido J, Blanco-Colio LM: Combined therapy with renin-angiotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria: effects on soluble TWEAK, PTX3, and flow-mediated dilation. Clin J Am Soc Nephrol 5:1174-1181, 2010
25. Morishita Y, Hanawa S, Chinda J, Iimura O, Tsunematsu S, Kusano E: Effects of aliskiren on blood pressure and the predictive biomarkers for cardiovascular disease in hemodialysis-dependent chronic kidney disease patients with hypertension. Hypertens Res 34:308-313, 2011
26. Stubbs JR, Idiculla A, Slusser J, Menard R, Quarles LD: Cholecalciferol supplementation alters calcitriol-responsive monocyte proteins and decreases inflammatory cytokines in ESRD. J Am Soc Nephrol 21:353-361, 2010
27. Matias PJ, Jorge C, Ferreira C, Borges M, Aires I, Amaral T, Gil C, Cortez J, Ferreira A: Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters. Clin J Am Soc Nephrol 5:905-911, 2010
28. Alborzi P, Patel NA, Peterson C, Bills JE, Bekele DM, Bunaye Z, Light RP, Agarwal R: Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. Hypertension 52:249-255, 2008
29. Caglar K, Yilmaz MI, Saglam M, Cakir E, Acikel C, Eyileten T, Yenicesu M, Oguz Y, Vural A, Carrero JJ, Axelsson J, Lindholm B, Stenvinkel P: Short-term treatment with sevelamer increases serum fetuin-a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients. Clin J Am Soc Nephrol 3:61-68, 2008
30. Vlassara H, Uribarri J, Cai W, Goodman S, Pyzik R, Post J, et al.: Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease. Clin J Am Soc Nephrol 7:934-942, 2012
31. Don BR, Kim K, Li J, Dwyer T, Alexander F, Kaysen GA: The effect of etanercept on suppression of the systemic inflammatory response in chronic hemodialysis patients. Clin Nephrol 73:431-438, 2010
32. Larsen CM, Faulenbach M, Vaag A, Volund A, Ehses JA, Seifert B, Mandrup-Poulsen T, Donath MY: Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 356:1517-1526, 2007
33. Hung AM, Ellis CD, Shintani A, Booker C, Ikizler TA: IL-1β receptor antagonist reduces inflammation in hemodialysis patients. J Am Soc Nephrol 22:437-442, 2011
34. Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium: Hingorani AD, Casas JP: The interleukin-6 receptor mendelian randomization analysis (IL6R MR) consortium. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet 379:1214-1224, 2012